Norway denies Novo Nordisk reimbursement for obesity drug
A similar decision not to offer subsidies to patients undergoing obesity treatment with Wegovy was also made by Denmark.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
The Norwegian Medicines Agency, SLV, has denied granting reimbursement for Novo Nordisk’s obesity drug, Wegovy (semaglutide), reports MedWatch’s Norwegian sister media.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
